The spray, Spravato, first received authorization in 2019 for use in combination with oral antidepressants in patients struggling with major depressive disorder. At the time, it marked the first ...
Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback